Value Sense
SMMT
Summit Therapeutics Inc. (SMMT)
Last Price$19.1(7.5%)
Market Cap$14.6B
Relative value
$0.5
Overvalued (Relative Value)
97.2%
NTM P/E
(64.6x)
Peer set median: 11.0x
1Y Fwd EV/EBITDA
(685.4x)
Peer set median: 9.1x
Stock quality
6/10
Good
SMMT
is 97.4% overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

SMMT Relative Value & Intrinsic Value

Key Highlights:
Relative Value vs Current Share Price
As of Mar 03, 2025 SMMT Relative Value is $0.5, which is overvalued by 97.2%, compared to current share price of $19.1.
DCF Value vs Current Share Price
As of Mar 03, 2025 SMMT DCF Value is N/A, which is undervalued by N/A, compared to current share price of $19.1.
Methodology
Price per share, $
SMMT
Intrinsic value$0.5
Overvalued by97.4%
Current share price
19.1
Relative value
0.5
DCF value
not available

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

SMMT Valuation Multiples comparison vs Peer Set

LTM
NTM
1Y Forward
2Y Forward
EV/Revenue

General

Valuation Multiple

Financial metrics

Company name

EV/Revenue

Revenue growth

EBITDA margin

Net Income margin

Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
N/A
N/A
(68.7%)
N/A
Median Peer Set
4.0x
18.9%
(41.2%)
12.6%
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
13.3x
23.0%
(38.6%)
(12.4%)
argenx SE logo
argenx SEARGX
N/A
198.6%
(60.5%)
(24.1%)
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
0.1x
73.7%
(56.5%)
(35.9%)
BioNTech SE logo
BioNTech SEBNTX
3.1x
(77.4%)
(89.7%)
24.4%
Incyte Corporation logo
Incyte CorporationINCY
3.0x
14.8%
(94.0%)
0.8%
Novo Nordisk A/S logo
Novo Nordisk A/SNVO
10.2x
24.9%
142.8%
34.8%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
4.1x
8.3%
10.4%
31.1%
Royalty Pharma plc logo
Royalty Pharma plcRPRX
6.3x
(3.8%)
(43.7%)
37.9%
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
3.8x
23.6%
25.7%
41.5%
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
11.0x
11.7%
N/A
(4.9%)

SMMT Valuation multiples overview

LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
N/A (as of Mar 03, 2025)
EV/Gross Profit
(211,518.0x) (as of Mar 03, 2025)
EV/EBIT
(67.2x) (as of Mar 03, 2025)
EV/EBITDA
(66.7x) (as of Mar 03, 2025)
EV/FCF
(99.7x) (as of Mar 03, 2025)
EV/OCF
(99.7x) (as of Mar 03, 2025)
P/Revenue
N/A (as of Mar 03, 2025)
P/Gross Profit
(217,564.9x) (as of Mar 03, 2025)
P/EBIT
(69.1x) (as of Mar 03, 2025)
P/EBITDA
(68.6x) (as of Mar 03, 2025)
P/FCF
(102.6x) (as of Mar 03, 2025)
P/OCF
(102.6x) (as of Mar 03, 2025)
P/E
(65.9x) (as of Mar 03, 2025)
P/BV
37.5x (as of Mar 03, 2025)
PEG 1Y
(9.7x) (as of Mar 03, 2025)

SMMT Valuation multiples history vs. Peer set

Crunching data... Almost there!

Explore more intrinsic value tools hub for SMMT

DCF value calculator
Peter Lynch Fair Value
Earnings Power Value
Intrinsic Value
Reverse DCF
Margin of safety
Peter Lynch charts
Earnings growth model
Ben Graham Fair Value
Discount rate

FAQ

What is Summit Therapeutics Inc. relative value?

As of Mar 03, 2025, Apple Relative Value is $0.5. This suggests it may be overvalued by 97.2% compared to its current price of around $19.1.

What is Summit Therapeutics Inc. DCF (discounted cash flow) valuation?

As of Mar 03, 2025, Summit Therapeutics Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at N/A. This suggests it may be overvalued by N/A to its current price of around $19.1, using a discount rate of 7.4% and terminal growth rate of 3.0%.

What is Summit Therapeutics Inc. intrinsic value?

As of Mar 03, 2025, Apple Intrinsic Value is $0.5. This suggests it may be overvalued by 97.4% compared to its current price of around $19.1.